BBNX Earnings & Financial Statements
Beta Bionics, Inc.
$18.95
-$0.01(-0.05%)
52
Overall
60
Value
50
Tech
47
Quality
Market Cap
$998.09M
Volume
624.63K
52W Range
$8.80 - $32.71
Target Price
$22.57
BBNX earnings and financial statements: Beta Bionics, Inc.'s income statement, balance sheet and cash flow statement, annual and quarterly.
BBNX Annual Financial Statements
| Fiscal year | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Revenue | $100.25M | $65.12M | $11.99M | -$179.0K |
| Cost of revenue | $44.71M | $29.24M | $5.69M | - |
| Operating income | -$71.68M | -$45.25M | -$35.85M | -$66.20M |
| EBITDA | -$70.33M | -$52.47M | -$41.94M | -$63.01M |
| Net income | -$73.20M | -$54.76M | -$44.10M | -$65.11M |
| EPS (diluted) | $-1.81 | $-8.60 | $-8.31 | $-12.96 |
| Fiscal year | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Total assets | $328.74M | $149.65M | $110.04M | $35.53M |
| Total liabilities | $41.13M | $73.63M | $51.43M | $22.53M |
| Shareholders’ equity | $287.61M | -$245.36M | -$20.07M | $13.00M |
| Cash and equivalents | $31.58M | $30.43M | $26.57M | $27.68M |
| Long-term debt | $5.37M | $5.73M | $3.00M | $3.16M |
| Fiscal year | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Operating cash flow | -$50.92M | -$48.27M | -$32.45M | -$60.21M |
| Capital expenditure | -$5.30M | -$3.35M | - | - |
| Free cash flow | -$56.22M | -$51.67M | -$32.85M | -$60.98M |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | BBNX | $18.95 | -0.1% | 624.63K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |